News 'Bionic eye' receives FDA fast-track review designation Review of Second Sight's Orion will now be streamlined.
News Ocugen shares fall, despite positive eye disorder trial A trial of Ocugen's gene therapy for sight-robbing disease geographic atrophy (GA) showed efficacy – but still sparked a selloff in its shares.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
